| World Health Organization classification of tumours of haematopoietic and lymphoid tissues SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, ... Lyon: IARC press, 2008 | 2287 | 2008 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 1688 | 2022 |
| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 469 | 2020 |
| Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics K Morita, F Wang, K Jahn, T Hu, T Tanaka, Y Sasaki, J Kuipers, S Loghavi, ... Nature communications 11 (1), 5327, 2020 | 277 | 2020 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 207 | 2021 |
| Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection L Pereira, M Petitt, A Fong, M Tsuge, T Tabata, J Fang-Hoover, E Maidji, ... The Journal of infectious diseases 209 (10), 1573-1584, 2014 | 140 | 2014 |
| Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ... Blood advances 4 (7), 1311-1320, 2020 | 130 | 2020 |
| Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients S Loghavi, K Alayed, TN Aladily, Z Zuo, SB Ng, G Tang, S Hu, CC Yin, ... Journal of hematology & oncology 8, 1-11, 2015 | 121 | 2015 |
| Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations S Loghavi, Z Zuo, F Ravandi, HM Kantarjian, C Bueso-Ramos, L Zhang, ... Journal of hematology & oncology 7, 1-10, 2014 | 121 | 2014 |
| Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease KL Graham, BA Zabel, S Loghavi, LA Zuniga, PP Ho, RA Sobel, ... The Journal of Immunology 183 (10), 6717-6723, 2009 | 109 | 2009 |
| DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease AE Quesada, MJ Routbort, CD DiNardo, CE Bueso‐Ramos, ... American journal of hematology 94 (7), 757-766, 2019 | 105 | 2019 |
| Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia A Maiti, CD DiNardo, NG Daver, CR Rausch, F Ravandi, TM Kadia, ... Blood cancer journal 11 (2), 25, 2021 | 99 | 2021 |
| Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax K Kim, A Maiti, S Loghavi, R Pourebrahim, TM Kadia, CR Rausch, ... Cancer 127 (20), 3772-3781, 2021 | 98 | 2021 |
| Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial NJ Short, HM Kantarjian, S Loghavi, X Huang, W Qiao, G Borthakur, ... The Lancet Haematology 6 (1), e29-e37, 2019 | 97 | 2019 |
| B-acute lymphoblastic leukemia/lymphoblastic lymphoma S Loghavi, JL Kutok, JL Jorgensen American journal of clinical pathology 144 (3), 393-410, 2015 | 93 | 2015 |
| Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? M Yilmaz, F Wang, S Loghavi, C Bueso-Ramos, C Gumbs, L Little, X Song, ... Blood cancer journal 9 (2), 7, 2019 | 84 | 2019 |
| Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL … L Deng, ZY Xu-Monette, S Loghavi, GC Manyam, Y Xia, C Visco, J Huh, ... Leukemia 30 (2), 361-372, 2016 | 82 | 2016 |
| Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia EJ Duncavage, A Bagg, RP Hasserjian, CD DiNardo, LA Godley, ... Blood, The Journal of the American Society of Hematology 140 (21), 2228-2247, 2022 | 80 | 2022 |
| Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation R Kanagal-Shamanna, S Loghavi, CD DiNardo, LJ Medeiros, ... Haematologica 102 (10), 1661, 2017 | 79 | 2017 |
| Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm N Sukswai, PP Aung, CC Yin, S Li, W Wang, SA Wang, V Ortega, ... The American journal of surgical pathology 43 (10), 1429-1437, 2019 | 70 | 2019 |
